Nuformix plc (LON:NFX – Get Free Report) fell 2.6% during trading on Tuesday . The stock traded as low as GBX 0.13 and last traded at GBX 0.15. Approximately 2,990,761 shares were traded during mid-day trading, a decline of 90% from the average session volume of 29,624,281 shares. The stock had previously closed at GBX 0.15.
Nuformix Stock Performance
The firm has a market cap of £4.85 million, a PE ratio of -6.35 and a beta of 1.52. The company’s 50-day simple moving average is GBX 0.17 and its two-hundred day simple moving average is GBX 0.19.
Nuformix (LON:NFX – Get Free Report) last issued its quarterly earnings data on Thursday, May 28th. The company reported GBX (0.02) EPS for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Stories
- Five stocks we like better than Nuformix
- Analog Devices’ AI Pivot Could Push Shares to Fresh Highs
- One Platform, Every Ailment: Hinge Health’s Gamble
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
